Sermorelin for women: what to know

Short version: sermorelin is a lab-made fragment of a natural hormone that nudges your own pituitary gland to release growth hormone, and it has become a regular in women’s anti-aging content. The pitch (fat loss, firmer muscle, better sleep, younger skin) runs well ahead of the human evidence. This page covers what sermorelin is, what the adult studies found, including one of the few that enrolled women in midlife and beyond, its side effects, and how it stacks up against tesamorelin, the related molecule it is most often compared with.

What is sermorelin and how does it work?

Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH), described in a drug review as “the shortest synthetic peptide with full biological activity of GHRH” (Prakash & Goa, BioDrugs, 1999). Rather than being growth hormone itself, it works one step upstream: it “binds to the growth hormone-releasing hormone receptor (GHRHR), mimicking the effects of the full-length GHRH” (Sermorelin, Wikipedia), which signals the pituitary to secrete its own growth hormone. Supporters argue this indirect route is gentler than injecting growth hormone, because the pituitary still governs how much is released. That mechanism is real, but a plausible mechanism is not the same as a proven midlife benefit.

It was once a prescription drug. Under the brand Geref it was used to test whether the pituitary can release growth hormone and to treat “idiopathic growth hormone deficiency (GHD) in children with growth failure,” until the maker discontinued it in 2008 (Federal Register, 2013).

Why does sermorelin keep coming up for women in midlife?

Because it fits a story that midlife feeds tell well. Natural growth hormone output declines with age, so a peptide that coaxes the body to make more of its own is framed as turning back that clock, and the claims aimed at women follow: fat loss around the middle, more lean muscle, deeper sleep, more energy and better skin. For a woman navigating stubborn midlife weight and body-composition changes it can sound like the missing piece. The trouble is not the theory. It is that almost none of those specific promises has been tested in women, and the few adult studies that exist point to modest hormonal changes rather than a visible transformation.

What does the evidence in adults actually show?

The evidence level is small human studies, mostly in older men, with no dedicated trial of sermorelin in women in perimenopause or menopause. The best-known adult study gave 11 healthy men aged 64 to 76 nightly sermorelin (GHRH 1-29) for six weeks. Growth hormone release rose, but there was “no change in GH pulse frequency or in levels of IGF-I,” and treatment “did not change weight, body mass index, waist to hip ratio, DEXA measures of muscle and fat” (Vittone et al., Metabolism, 1997). Two of six strength measures and one endurance test did improve, and the authors suggested single nightly doses were “less effective than multiple daily doses.” In other words, the hormone signal moved, but IGF-1, the downstream marker most tied to tissue effects, and body composition did not. PeptideAgent’s sermorelin profile also rates the adult evidence as limited, and records that its former FDA approval as Geref was withdrawn in 2009 for reasons FDA confirmed were not about safety or effectiveness.

For context, even growth hormone itself, given to healthy older men in a randomized trial, increased lean mass and cut fat mass but did not improve strength or endurance, and side effects “occurred frequently” (Papadakis et al., Ann Intern Med, 1996). Moving a scan number is not the same as feeling or functioning better.

Does sermorelin work for women?

The closest data in women comes from a close analog of sermorelin, and the results favored men. In a small single-blind study, 10 women and 9 men aged 55 to 71 took placebo injections for 4 weeks and then a modified GHRH(1-29) for 16 weeks. In both sexes growth hormone and IGF-1 rose (IGF-1 drifted back toward baseline by week 16) and skin thickness increased, but lean body mass rose “in men only,” insulin sensitivity, general well-being and libido improved in men “but not in women,” and “sleep quality was unaffected in both genders” (Khorram et al., J Clin Endocrinol Metab, 1997). The authors concluded the effects were anabolic “favoring men more than women.” That is one small study of a related molecule, not sermorelin itself, so it cannot settle the question either way, but it is the most direct look at women in this age range that we found.

What are the side effects of sermorelin?

The recorded side effects are mild, but the record is thin. In children, transient facial flushing and pain at the injection site were “the most commonly reported adverse events” (Prakash & Goa, 1999). The six-week study in older men reported “no significant adverse effects” (Vittone et al., 1997), and in the study that included older women, the only adverse side effect was “transient hyperlipidemia” (a temporary rise in blood fats) that resolved by the end of the study (Khorram et al., 1997). Fewer reported side effects mostly reflects fewer and smaller studies, not a proven clean profile, and none of these studies ran long enough to say much about years of use.

Sermorelin vs tesamorelin: what is the difference?

Both are lab-made versions of GHRH, but tesamorelin is the full molecule with a far deeper evidence base. The Egrifta SV label describes tesamorelin as “the 44 amino acid sequence of human GRF” with a short chemical chain attached, and it is a current prescription drug “indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy,” with the limit that it is “not indicated for weight loss management” (Egrifta SV label, DailyMed). In its pivotal randomized trial of 412 patients with HIV, 86% of whom were men, visceral fat “decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group” (Falutz et al., NEJM, 2007). That is a much bigger and better-controlled body of evidence than sermorelin has, though it was mostly in men with HIV, not midlife women. Our sister site lays the two side by side in detail in tesamorelin vs sermorelin, and the hub covers the drug on its own in its tesamorelin overview.

Sources for the table: sermorelin rows from Prakash & Goa (1999), Vittone et al. (1997) and Khorram et al. (1997); tesamorelin rows from the Egrifta SV label and Falutz et al. (2007).

Is sermorelin worth it for women in menopause?

For most women in midlife, it is not the strongest tool available, and it should not be the first one considered. The changes that drive so much midlife frustration (weight settling around the middle, disrupted sleep, mood and energy shifts) are better served first by options with real evidence, starting with menopausal hormone therapy where it fits and, for weight, the approved branded GLP-1 medicines. Our explainer on peptides vs HRT for menopause, the companion piece on whether peptides can help with menopause symptoms and the overview of peptides and metabolic care for women all land in the same place: peptides like sermorelin are, at best, a secondary conversation, not a replacement for the therapies that carry the evidence. On cost, we have not verified a current price for sermorelin, so this page does not quote one; it is also not sold by the store this network links to.

What are people saying about sermorelin online?

We do not have a dedicated Community Insights summary for sermorelin, but it comes up in our summaries of public posts on X about CJC-1295 (17 posts) and ipamorelin (16 posts), analyzed in July 2026. These are anecdotes, not evidence.

• One family. Commenters group sermorelin with tesamorelin, CJC-1295 and ipamorelin under the label “GH secretagogues” and weigh them against each other on cost.
• The ranking. One shared tier list placed sermorelin in the same tier as CJC-1295 and ipamorelin, below growth hormone itself and tesamorelin.
• The “approved one.” Users note that tesamorelin is the only approved GHRH analog.

Notably, none of those summaries center on women or menopause, which is a gap between the women’s anti-aging marketing and the conversations actually happening about these compounds.

Status: Not currently FDA-approved; its former brand, Geref, was withdrawn in 2009, a withdrawal the FDA determined was not for reasons of safety or effectiveness. What these status terms mean.

Sermorelin at a glance

Sources and further reading

Every clinical and historical statement on this page traces to a primary or authoritative source, listed here so you can verify it directly.

• Sermorelin (Wikipedia), structure and mechanism
• Federal Register (2013): Determination that Geref (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness
• Vittone et al., Effects of single nightly injections of GHRH (1-29) in healthy elderly men (Metabolism, 1997)
• Khorram et al., Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women (J Clin Endocrinol Metab, 1997)
• Prakash & Goa, Sermorelin: a review of its use in children with idiopathic growth hormone deficiency (BioDrugs, 1999)
• Papadakis et al., Growth hormone replacement in healthy older men improves body composition but not functional ability (Ann Intern Med, 1996)
• Falutz et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV (NEJM, 2007)
• Egrifta SV (tesamorelin) prescribing information, DailyMed